Introduction {#sec1_1}
============

Alzheimer\'s disease (AD) is the most common form of dementia accounting for between 50 and 70% of cases globally \[[@B1],[@B2]\]. The presence of intracellular neurofibrillary tangles, extracellular neuritic plaques, and brain-wide neurodegeneration are key pathological features which define AD \[[@B3]\]. Other pathological processes associated with AD include altered levels of neurotransmitter receptor expression \[[@B4]\] as well as dysregulation of cell signaling \[[@B5],[@B6],[@B7]\], inflammatory response \[[@B8],[@B9]\], synaptic transmission \[[@B10],[@B11],[@B12]\], and cholesterol metabolism \[[@B13],[@B14]\]. At present, a complete understanding of the underlying causes of these pathogenic processes remains elusive. It is predicted that there is a common underlying process that is dysregulated in AD, which serves as a convergence point that links the multitude of dysfunctional signatures.

Alternative splicing is a widespread gene-regulatory process by which exons of primary transcripts (pre-mRNAs) are spliced into different arrangements to produce structurally distinct mRNA variants. This mechanism of gene product diversification plays a critical role in controlling cellular differentiation and development in response to environmental, temporal, or cell type-specific cues \[[@B15],[@B16]\]. It is estimated that more than 75% of genes in the human genome are alternatively spliced \[[@B17]\]. Dysregulation in alternative splicing has been linked to a number of human diseases including some neurodegenerative diseases (e.g. frontotemporal dementia with parkinsonism) \[[@B18]\]. However, in AD, few studies have investigated the link between alternative splicing dysregulation, aberrant splice-regulatory protein expression, and AD progression. In a recent study, it has been found that generation of the tropomyosin receptor kinase B (TrkB) alternative transcript TrkB-Shc is regulated by the serine/arginine protein Srp20, and that biochemical manipulation of its expression in neuronal cell lines and exposure of cells to amyloidogenic factors could modulate TrkB pre-mRNA splicing and TrkB-Shc expression \[[@B19]\]. In other dementias, alterations in the levels of splice-regulatory protein expression have been shown to affect alternative splicing in frontotemporal dementia with parkinsonism. For instance, in humans, alterations in adult-specific tau exon 10 splicing have been demonstrated to lead to abnormal ratios of tau isoform expression \[[@B20],[@B21],[@B22]\]. Considering that one splice-regulatory protein is capable of regulating the splicing of multiple pre-mRNAs, it is hypothesized that dysregulation of pre-mRNA splicing from the altered expression of key splice-regulatory proteins in AD may underlie the aberrant changes in gene expression in multiple AD-affected pathways during disease progression.

Materials and Methods {#sec1_2}
=====================

Datasets {#sec2_1}
--------

The hippocampal CA1 microarray datasets derived from postmortem brain tissue from a total of 31 subjects − 9 controls and 22 AD subjects -- of varying AD severity (n = 7 incipient, n = 8 moderate, and n = 7 severe) were obtained from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (Affymetrix GeneChip (HG-U133A); accession GDS810 \[[@B23]\] and GSE28146 \[[@B24]\]). Cohort demographics are listed in table [1](#T1){ref-type="table"}.

To determine whether there are changes in splice-regulatory protein gene expression during AD progression, expression profiles of all genes involved in RNA splicing were collated from the GDS810 microarray. Genes that were statistically significant by one-way analysis of variance (ANOVA) with a p value \<0.05 or showed a trend towards statistical significance with a p value range between 0.05 and 0.1 were then mined from the GSE28146 microarray. Considering that a specific group of genes were to be assessed, all gene expression profiles were included, even those with low expression.

Statistical Analysis {#sec2_2}
--------------------

Statistical analyses were conducted using Statistica 7 (StatSoft Inc., 2000, Statistica for Windows). One-way ANOVA was conducted to assess changes in gene expression during AD progression. ANOVAs were followed up with the Fisher LSD post hoc analysis to assess significance in gene expression between AD severity groups. Pearson\'s product moment correlations were used to determine whether any relationship existed between splice-regulatory protein gene expression and the expression of AD susceptibility genes. A p value \<0.05 (two-tailed) was considered statistically significant.

Results {#sec1_3}
=======

In this current report, two publically available microarray datasets from a control/AD hippocampal brain cohort from the NCBI GEO database (Affymetrix GeneChip (HG-U133A); accession GDS810 \[[@B23]\] and GSE28146 \[[@B24]\]) were utilized. In both studies \[[@B23],[@B24]\], the expression of genes significantly altered in AD was classified into functional categories and biological pathways of the gene ontology consortium ([www.geneontology.org](http://www.geneontology.org)). However, a specific category for genes involved in RNA splicing was not described and genes involved in RNA splicing were likely grouped into other gene ontology categories. Thus, to determine whether genes involved in RNA splicing are altered during AD progression, genes whose gene products are known to be involved (either directly or indirectly) in RNA splicing were screened.

GDS810 Microarray {#sec2_3}
-----------------

The GDS810 microarray published by Blalock et al. \[[@B23]\] assessed gene expression changes in the hippocampal CA1 subfield from a total of 31 subjects − 9 controls and 22 AD subjects -- of varying AD severity. A total of 22,286 genes were tested and of these, 499 were involved in RNA splicing. Of the 499 genes, only 45 were found to be altered from the incipient stage of AD to the severe stage (table [2](#T2){ref-type="table"}). Specifically, 6 of the 45 genes identified were significantly changed in subjects with incipient AD. Interestingly, hnrnpA3 was the only gene that showed a significant decrease in expression, whereas NUDT21, LSM5, hnrnpUL1, RBM8A, and RBMY1J were significantly increased in expression. In subjects with moderate AD, the expression of 18 genes was found to be significantly altered compared to controls. Of these, 5 genes were significantly decreased, whereas 13 genes were significantly increased. In subjects with severe AD, 21 genes were found to be significantly changed compared to controls. Of these, 6 genes showed a significantly reduced expression, whereas 15 showed a significantly increased expression.

It is worth noting that while 45 genes were found to be significantly altered during AD progression, the expression of 34 genes trended towards statistical significance (one-way ANOVA: 0.05 \< p \< 0.1) (table [3](#T3){ref-type="table"}). Of these, 11 were decreased in expression and 23 were increased in expression.

GSE28146 Microarray {#sec2_4}
-------------------

In the GSE28146 microarray published by Blalock et al. \[[@B24]\], grey matter of the hippocampal CA1 subfield was selectively isolated using laser capture microdissection from the same subjects and analyzed for gene expression changes. Using this dataset, the expression of splice-regulatory proteins that were significantly altered or showed a trend towards statistical significance in AD in the GDS810 microarray was screened to determine whether changes in gene expression were specific to the grey matter. Of the 45 genes that were significantly changed throughout the course of AD in the GDS810 microarray study, only QKI, PTBP1, and SFPQ were significantly altered in the GSE28146 microarray (table [4](#T4){ref-type="table"}). Of the 34 genes that trended towards significance in the GDS810 microarray study, SRSF7, SFRS16, and YTHDC1 were found to be significantly changed in the GSE28146 study.

It was next determined whether the splice-regulatory proteins found to be significantly altered in both the GDS810 and GSE28146 microarray studies correlated in their gene expression pattern over the disease duration. Interestingly, QKI and SRSF7 were the only two genes showing concordance (table [5](#T5){ref-type="table"}).

Gene Expression Correlations between Splice-Regulatory Proteins and AD Susceptibility Genes {#sec2_5}
-------------------------------------------------------------------------------------------

Next, it was determined whether changes in splice-regulatory protein expression found to be significant in both the GDS810 and GSE28146 microarray studies correlated with gene expression changes of various transcripts reported to be altered in AD. These included progranulin (GRN), microtubule-associated protein tau (MAPT), presenilin-1 (PSEN1), presenilin-2 (PSEN2), presenilin enhancer protein 2 (PSENEN), amyloid beta (A4) precursor protein (APP), apolipoprotein E (APOE), TrkB (NTRK2), and brain-derived neurotrophic factor (BDNF) \[[@B25],[@B26],[@B27],[@B28],[@B29]\]. While the expression of most transcripts correlated with expression levels of the splice-regulatory proteins in their respective studies, only APP and TrkB transcripts correlated significantly with the same splice-regulatory proteins in the two studies (tables [6](#T6){ref-type="table"}, [7](#T7){ref-type="table"}). Two APP transcripts showed significant positive correlations with YTHDC1, whereas one transcript showed a negative correlation. The TrkB transcripts showing significant correlations with splice-regulatory protein expression were those encoding the C-terminal truncated TrkB isoform TrkB-TK-. TrkB-TK- transcripts correlated negatively with SRSF7 and SFRS16 but positively with SFPQ expression throughout AD progression.

Discussion {#sec1_4}
==========

In the two microarray datasets utilized in this study, most changes in gene expression were found to occur during the moderate to severe stages of AD, periods coinciding with gross pathological brain changes and cognitive decline \[[@B30]\], whereas fewer changes occurred during the incipient stage of AD. Interestingly, of the 45 splice-regulatory proteins whose gene expression was found to be significantly altered in the GDS810 microarray study, only 6 were significant in the GSE28146 study; moreover, these significant changes in gene expression occurred during the incipient stages of AD. This finding suggests that changes in splice-regulatory protein expression may occur in the grey matter early in the disease process, prior to gross pathological brain changes. Indeed, when the GDS810 and GSE28146 microarrays were assessed to determine whether those splicing proteins found to be significantly altered in both microarray studies correlated in their gene expression pattern over the disease duration, QKI and SRSF7 were the only two genes showing concordance. The lack of concordance in splice-regulatory protein expression between the two microarray studies suggests that the majority of gene expression changes in the GDS810 study were likely influenced by changes in the white matter, which was largely excluded by the laser capture microdissection in the GSE28146 study.

Relationship between Splice-Regulatory Proteins and AD Susceptibility Genes {#sec2_6}
---------------------------------------------------------------------------

When it was assessed whether the expression of splice-regulatory proteins found to be significantly altered in AD correlated with the expression levels of AD susceptibility genes, significant correlations in APP and TrkB-TK- transcripts throughout AD progression in both the GDS810 and GSE28146 microarray studies suggest that changes in gene expression may be primarily influenced by changes in the grey matter, which is consistent with the cellular expression of APP (expressed primarily in neurons and glia and to a lesser extent in endothelial cells) and TrkB-TK- (expressed principally by astrocytes and to a lesser extent by neurons) \[[@B31],[@B32],[@B33]\]. The APP transcripts showing a significant correlation with YTHDC1 were targeted by pan probes, whereas the TrkB transcripts showing significant correlations with SRSF7, SFRS16, and SPQF were targeted by probes specific for the transcript variant encoding TrkB-TK-. These findings suggest that YTHDC1 may be involved in regulating constitutive splicing of the APP pre-mRNA rather than regulating alternative splicing of specific exons.

The TrkB-TK- transcript variant encodes a TrkB protein isoform truncated at the C terminus and in comparison to the full-length receptor, and thus cannot partake in classical receptor tyrosine kinase signaling \[[@B34],[@B35],[@B36]\]. This is due to alternative exon splicing of the pre-mRNA where exon 16 is incorporated into the final transcript. Exon 16 encodes a translation stop codon and polyadenylation sequence; thus, transcripts are differentially regulated posttranscriptionally \[[@B34],[@B36]\]. The finding that TrkB-TK- transcript levels correlated with the same splice-regulatory proteins significantly altered in both microarray studies implicates these splice-regulatory proteins as potential regulators of TrkB-TK- expression. In particular, SRSF7 has previously been demonstrated to be a regulator of tau alternative splicing \[[@B20]\]. Abnormal ratios of tau isoforms 3R and 4R (imperfect repeats of approximately 32 amino acids in the microtubule-binding domain) lead to tau aggregation and neurofibrillary tangle formation. The generation of tau isoforms 3R and 4R is determined by alternative mRNA splicing of exon 10 \[[@B20],[@B21],[@B22]\], and point mutations in the splice-regulatory region affecting SRSF7 binding have been shown to modulate inclusion/exclusion of tau exon 10 \[[@B20]\]. In both the GDS810 and GSE28146 microarray studies, the probes targeted to MAPT transcripts (gene encoding tau) were not specific for exon 10 detection, thus no significant correlation between changes in SRSF7 and MAPT expression was found. However, MAPT expression is likely to be regulated by additional mechanisms. Considering that SRSF7 was one of only two splice-regulatory proteins to be significantly and positively correlated between the two microarray studies and is significantly correlated with TrkB-TK- transcript levels in the two studies, the findings reported here implicate SRSF7 as a potential regulator of TrkB pre-mRNA splicing in the production of TrkB-TK- alternative transcripts in the grey matter. The lack of concordance between SFRS16 and SPQF gene expression changes between the GDS810 and GSE28146 microarray studies suggests that these two splice-regulatory proteins may function in regulating TrkB-TK- transcript levels in the white matter.

Conclusion {#sec1_5}
==========

Dysregulation in splice-regulatory protein gene expression can adversely affect alternative splicing and gene expression of a number of cellular processes. The findings reported in this study offer mechanistic insight into how aberrant changes in alternative transcript expression may occur in AD and highlight a susceptibility network -- splice-regulatory proteins -- which can potentially link a number of susceptibility genes/pathways.
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###### 

Cohort demographics

                   Gender   Age, years
  ---------------- -------- ------------
  Control 976      male     85
  Control 1003     male     80
  Control 1008     female   92
  Control 1012     male     80
  Control 1015     male     75
  Control 1018     female   97
  Control 1030     male     95
  Control 1039     male     77^a^
  Control 1040     male     87
  Incipient 715    female   101
  Incipient 720    female   95
  Incipient 994    female   83
  Incipient 1019   male     88
  Incipient 1029   female   91
  Incipient 1034   male     88
  Incipient 1043   female   97
  Moderate 826     female   85
  Moderate 832     female   89
  Moderate 856     female   83
  Moderate 965     female   82
  Moderate 1020    female   79
  Moderate 1025    male     81
  Moderate 1031    female   86
  Moderate 1037    male     82
  Severe 701       male     85
  Severe 723       female   65
  Severe 807       male     93
  Severe 819       female   79
  Severe 867       female   94
  Severe 872       female   79
  Severe 1036      female   93

Control 1039 is excluded in the GSE28146 microarray.

###### 

Microarray gene expression changes in the CA1 hippocampus (p \< 0.05; GDS810 microarray)

  Probe          Gene           Description                                                               Control           Incipient         Moderate           Severe              ANOVA F   ANOVA p
  -------------- -------------- ------------------------------------------------------------------------- ----------------- ----------------- ------------------ ------------------- --------- -----------------------------------------
  206809_s\_at   HNRNPA3        heterogeneous nuclear ribonucleoprotein A3                                461.2 ± 62.2      305.9 ± 48.3      362.1 ± 53         222.1 ± 38.4        3.63      0.03[^a^](#T2F1){ref-type="table-fn"}
  208713_at      HNRNPUL1       heterogeneous nuclear ribonucleoprotein U-like 1                          610.9 ± 39.4      809.7 ± 72.7      757.5 ± 38.8       836.6 ± 67          3.73      0.02[^a^](#T2F1){ref-type="table-fn"}
  202903_at      LSM5           U6 snRNA-associated Sm-like protein LSm5                                  108.8 ± 10.6      167.5 ± 19.9      162.5 ± 7.9        186.5 ± 29.8        3.79      0.02[^a^](#T2F1){ref-type="table-fn"}
  202697_at      NUDT21         nucleoside diphosphate-linked moiety X                                    135.4 ± 10.8      188.6 ± 14.2      136 ± 14           141.2 ± 14.4        3.54      0.03[^a^](#T2F1){ref-type="table-fn"}
  213852_at      RBM8A          RNA-binding motif protein 8A                                              1,490.1 ± 72.1    1,899.7 ± 104     1,806 ± 80.1       1,887.6 ± 173.1     3.39      0.03[^a^](#T2F1){ref-type="table-fn"}
  216842_x\_at   RBMY1J         RNA-binding motif protein, Y-linked, family 1, member J                   144.1 ± 19.4      275.9 ± 42.7      156.5 ± 26.7       232.1 ± 48.3        3.37      0.03[^a^](#T2F1){ref-type="table-fn"}
  207842_s\_at   CASC3          cancer susceptibility candidate 3                                         1,372.3 ± 115.2   1,646.7 ± 183.4   2,256.4 ± 256.3    2,198.7 ± 212.3     5.12      0.006[^b^](#T2F2){ref-type="table-fn"}
  203376_at      CDC40          cell division cycle 40 homolog                                            1,291.1 ± 84.1    1,174.3 ± 91.9    913.5 ± 73.4       1,033.8 ± 67.7      4.46      0.01[^b^](#T2F2){ref-type="table-fn"}
  201077_s\_at   NHP2L1         nonhistone chromosome protein 2-like 1                                    1,995.8 ± 74.2    1,764 ± 105.5     1,599.1 ± 42.9     1,487.1 ± 107.8     7.39      0.0009[^b^](#T2F1){ref-type="table-fn"}
  200057_s\_at   NONO           non-POU domain-containing octamer binding                                 3,671.8 ± 98.9    3,872.7 ± 103.9   4,017.1 ± 164.8    4,171.8 ± 110.5     3.07      0.04[^b^](#T2F2){ref-type="table-fn"}
  202635_s\_at   POLR2K         polymerase (RNA) II (DNA-directed) polypeptide K, 7.0 kDa                 465.9 ± 61.3      367.5 ± 44.5      253.2 ± 22.6       409.4 ± 46.2        3.85      0.02[^b^](#T2F2){ref-type="table-fn"}
  208652_at      PPP2CA         serine/threonine protein phosphatase 2A catalytic subunit alpha isoform   3,154.9 ± 298.8   2,558.9 ± 234.3   2,255.6 ± 130.1    1,840.5 ± 278.6     5.15      0.006[^b^](#T2F2){ref-type="table-fn"}
  221547_at      PRPF18         PRP18 pre-mRNA processing factor 18 homolog                               220 ± 15.2        239 ± 11.9        161.4 ± 17.1       258.2 ± 21          6.25      0.002[^b^](#T2F2){ref-type="table-fn"}
  218053_at      PRPF40A        PRP40 pre-mRNA processing factor 40 homolog A                             876 ± 73.5        979.3 ± 63        1,334.4 ± 125.6    1,193.6 ± 79.9      5.54      0.004[^b^](#T2F2){ref-type="table-fn"}
  211270_x\_at   PTBP1          polypyrimidine tract-binding protein 1                                    565.9 ± 50.9      683.1 ± 78.9      850.1 ± 87.4       870.1 ± 76          4.1       0.02[^b^](#T2F2){ref-type="table-fn"}
  211271_x\_at   PTBP1          polypyrimidine tract-binding protein 1                                    491.9 ± 36.7      568.4 ± 84.5      772.8 ± 72.8       654.6 ± 57.2        3.91      0.02[^b^](#T2F2){ref-type="table-fn"}
  212015_x\_at   PTBP1          polypyrimidine tract-binding protein 1                                    362.4 ± 28.4      388.6 ± 67.6      536.2 ± 44.8       448.3 ± 40.2        3.04      0.046[^b^](#T2F2){ref-type="table-fn"}
  216306_x\_at   PTBP1          polypyrimidine tract-binding protein 1                                    655 ± 76.3        762.9 ± 66.6      1,021.3 ± 100.7    962.4 ± 90.4        4.26      0.01[^b^](#T2F2){ref-type="table-fn"}
  212262_at      QKI            homolog of mouse quaking QKI                                              534.1 ± 33.4      673.4 ± 56.8      758.8 ± 46.4       820.6 ± 100.2       4.49      0.01[^b^](#T2F2){ref-type="table-fn"}
  212636_at      QKI            homolog of mouse quaking QKI                                              7,246.6 ± 762.9   9,010.5 ± 882.5   11,098.5 ± 793.3   10,982.3 ± 1262.1   4.24      0.01[^b^](#T2F2){ref-type="table-fn"}
  215089_s\_at   RBM10          RNA-binding motif protein 10                                              261.3 ± 48.8      219.1 ± 47.1      463.6 ± 48.3       314.2 ± 84.7        3.45      0.03[^b^](#T2F2){ref-type="table-fn"}
  207941_s\_at   RBM39          RNA-binding motif protein 39                                              3,192.2 ± 118.6   3,276.6 ± 263     4,108.2 ± 117.8    3,436.4 ± 238.7     5.32      0.005[^b^](#T2F2){ref-type="table-fn"}
  219507_at      RSRC1          arginine/serine-rich coiled-coil 1                                        66.8 ± 12.9       85.2 ± 18.1       123.3 ± 8.45       159.6 ± 30.8        5.1       0.006[^b^](#T2F2){ref-type="table-fn"}
  221768_at      SFPQ           splicing factor proline/ glutamine rich                                   794.7 ± 40.6      861.6 ± 83.5      1,137.9 ± 126.6    780.4 ± 104.9       3.37      0.03[^b^](#T2F2){ref-type="table-fn"}
  216364_s\_at   AFF2           AF4/FMR2 family, member 2                                                 15.2 ± 1.96       24.1 ± 4.26       23.1 ± 6.56        65.9 ± 23.5         3.92      0.02[^c^](#T2F3){ref-type="table-fn"}
  203809_s\_at   AKT2           RAC-beta serine/threonine-protein kinase                                  64.4 ± 13.9       75.9 ± 9.3        79.9 ± 11.6        131 ± 20            4.16      0.02[^c^](#T2F3){ref-type="table-fn"}
  202256_at      CD2BP2         CD2 (cytoplasmic tail)-binding protein 2                                  365 ± 20.1        381.7 ± 34.1      411.4 ± 28.2       522.8 ± 43.4        4.98      0.007[^c^](#T2F3){ref-type="table-fn"}
  209056_s\_at   CDC5L          cell division cycle 5-like protein                                        676.3 ± 36.6      623.8 ± 48.4      578.1 ± 25.7       492.2 ± 40.9        4.21      0.01[^c^](#T2F3){ref-type="table-fn"}
  219539_at      GEMIN6         gem (nuclear organelle)-associated protein 6                              143.5 ± 18.9      130.8 ± 14.7      174 ± 15.4         214.5 ± 26.5        3.5       0.03[^c^](#T2F3){ref-type="table-fn"}
  210588_x\_at   HNRNPH3        heterogeneous nuclear ribonucleoprotein H3                                486.2 ± 39.8      578.9 ± 62.8      424.5 ± 34.7       689.7 ± 92.5        3.82      0.02[^c^](#T2F3){ref-type="table-fn"}
  202072_at      HNRNPL         heterogeneous nuclear ribonucleoprotein L                                 692.3 ± 82.2      746.9 ± 99        694.9 ± 63.6       380 ± 81.3          3.86      0.02[^c^](#T2F3){ref-type="table-fn"}
  220764_at      LOC100132773   serine/threonine-protein phosphatase 4-regulatory subunit 2-like          50 ± 13.9         21.1 ± 9.33       62.5 ± 15.4        96.8 ± 25.3         3.25      0.04[^c^](#T2F3){ref-type="table-fn"}
  217415_at      POLR2A         polymerase (RNA) II (DNA-directed) polypeptide A, 220 kDa                 76.1 ± 13.3       56.8 ± 14.3       81 ± 14.2          136 ± 26.6          3.55      0.03[^c^](#T2F3){ref-type="table-fn"}
  202634_at      POLR2K         polymerase (RNA) II (DNA-directed) polypeptide K, 7.0 kDa                 850 ± 66.5        836.7 ± 57.5      789.2 ± 34.9       590.1 ± 68.8        3.95      0.02[^c^](#T2F3){ref-type="table-fn"}
  202494_at      PPIE           peptidylprolyl isomerase E (cyclophilin E)                                206.1 ± 16.9      281.4 ± 53.7      262 ± 18.9         360.4 ± 40.7        3.7       0.02[^c^](#T2F3){ref-type="table-fn"}
  203103_s\_at   PRPF19         PRP19/PSO4 pre-mRNA-processing factor 19 homolog                          1,384.9 ± 112.7   1,182.1 ± 119.7   1,138.3 ± 89.3     879.1 ± 86.8        4.01      0.02[^c^](#T2F3){ref-type="table-fn"}
  218088_s\_at   RRAGC          Ras-related GTP-binding C                                                 1,081.5 ± 52.4    1,013.4 ± 82.1    1,218.4 ± 67.1     1,411.2 ± 69.2      6.43      0.002[^c^](#T2F3){ref-type="table-fn"}
  201070_x\_at   SF3B1          splicing factor 3b, subunit 1, 155 kDa                                    501.4 ± 44.3      517.2 ± 28.9      536.4 ± 53.8       829.1 ± 163.4       3.27      0.04[^c^](#T2F3){ref-type="table-fn"}
  217608_at      SFRS12IP1      SREK1-interacting protein 1                                               68.4 ± 6.13       62.8 ± 10.1       86.7 ± 13.1        122.1 ± 12.6        6.02      0.003[^c^](#T2F3){ref-type="table-fn"}
  218493_at      SNRNP25        small nuclear ribonucleoprotein, 25 kDa (U11/U12)                         1,080.4 ± 83      1,070.7 ± 113.3   1,019.8 ± 59.2     714.5 ± 41.7        4.52      0.01[^c^](#T2F3){ref-type="table-fn"}
  200826_at      SNRPD2         small nuclear ribonucleoprotein D2 polypeptide, 16.5 kDa                  2,611.4 ± 94      2,699 ± 193.7     2,648.4 ± 106.6    2,012.6 ± 251.4     3.64      0.03[^c^](#T2F3){ref-type="table-fn"}
  211439_at      SRSF7          serine/arginine-rich splicing factor 7 (9G8)                              137.5 ± 19.8      199.5 ± 43.3      124.1 ± 11.9       235.7 ± 31.4        3.61      0.03[^c^](#T2F3){ref-type="table-fn"}
  210180_s\_at   TRA2B          transformer-2 protein homolog beta                                        22.2 ± 4.97       6.97 ± 1.06       16.9 ± 6.27        34.6 ± 9.26         3.3       0.04[^c^](#T2F3){ref-type="table-fn"}
  206067_s\_at   WT1            Wilms tumor 1                                                             8.11 ± 1.46       12.1 ± 3.63       13.3 ± 3.26        21.1 ± 3.38         3.41      0.03[^c^](#T2F3){ref-type="table-fn"}
  214759_at      WTAP           Wilms tumor 1-associated protein                                          142.9 ± 25.7      174.5 ± 19.6      130 ± 12           216.4 ± 26          2.99      0.049[^c^](#T2F3){ref-type="table-fn"}

Incipient p \< 0.05 (Fisher LSD);

moderate p \< 0.05 (Fisher LSD);

severe p \< 0.05 (Fisher LSD).

###### 

Microarray gene expression changes in the CA1 hippocampus (0.05 \< p \< 0.1; GDS810 microarray)

  Probe          Gene      Description                                                  Control           Incipient         Moderate          Severe            ANOVA F   ANOVA p
  -------------- --------- ------------------------------------------------------------ ----------------- ----------------- ----------------- ----------------- --------- ---------------------------------------
  200041_s\_at   BATI      spliceosome RNA helicase DDX39B                              2,839.2 ± 220.5   3,233.4 ± 249     3,948.7 ± 274     3,076.4 ± 412.2   2.9       0.05[^a^](#T3F1){ref-type="table-fn"}
  209055_s\_at   CDC5L     cell division cycle 5-like protein                           130.2 ± 19.2      256.1 ± 66.6      126.1 ± 21.6      149.1 ± 35.9      2.53      0.08[^a^](#T3F1){ref-type="table-fn"}
  215045_at      CELF3     CUGBP, Elav-like family member 3                             631.6 ± 98.2      537 ± 59.6        669.9 ± 87        389.9 ± 43.4      2.33      0.1[^a^](#T3F1){ref-type="table-fn"}
  203947_at      CSTF3     cleavage stimulation factor, 3′ pre-RNA, subunit 3, 77 kDa   802 ± 58.7        786.8 ± 65.6      740.2 ± 68.9      1,000 ± 98.5      2.34      0.1[^a^](#T3F1){ref-type="table-fn"}
  219149_x\_at   DBR1      debranching enzyme homolog 1                                 129.2 ± 11.6      173.5 ± 15.8      171 ± 9.40        172.3 ± 18.2      2.73      0.06[^a^](#T3F1){ref-type="table-fn"}
  219121_s\_at   ESRP1     epithelial splicing-regulatory protein 1                     73.9 ± 19.5       40.1 ± 7.51       31.7 ± 3.72       81.4 ± 21.8       2.47      0.08[^a^](#T3F1){ref-type="table-fn"}
  200959_at      FUS       fused in sarcoma                                             797.9 ± 56.5      999.8 ± 59.8      821.5 ± 32.5      841.9 ± 73.8      2.5       0.08[^a^](#T3F1){ref-type="table-fn"}
  215744_at      FUS       fused in sarcoma                                             127.3 ± 14.9      88.3 ± 21.6       122.8 ± 11.8      160.7 ± 26.1      2.3       0.1[^a^](#T3F1){ref-type="table-fn"}
  202354_s\_at   GTF2F1    general transcription factor IIF, polypeptide 1, 74 kDa      95.5 ± 15.5       144.4 ± 20        75.2 ± 21.9       80 ± 19.5         2.53      0.08[^a^](#T3F1){ref-type="table-fn"}
  35201_at       HNRNPL    heterogeneous nuclear ribonucleoprotein L                    1,963.2 ± 158     2,212 ± 171       2,120.6 ± 118.2   1,689.6 ± 84.3    2.45      0.09[^a^](#T3F1){ref-type="table-fn"}
  214918_at      HNRNPM    heterogeneous nuclear ribonucleoprotein M                    66.1 ± 10.2       72.8 ± 16.7       90.9 ± 21.3       136.3 ± 27        2.66      0.07[^a^](#T3F1){ref-type="table-fn"}
  219814_at      MBNL3     muscleblind-like 3                                           33.5 ± 9.70       13.5 ± 3.45       42 ± 16           67.5 ± 20.9       2.39      0.09[^a^](#T3F1){ref-type="table-fn"}
  212718_at      PAPOLA    poly(A) polymerase alpha                                     2,442.8 ± 240.9   2,252.2 ± 428.9   2,644.5 ± 251.4   3,686 ± 610.5     2.55      0.08[^a^](#T3F1){ref-type="table-fn"}
  203378_at      PCF11     cleavage and polyadenylation factor subunit, homolog         491 ± 41.8        533.8 ± 55.3      673.7 ± 50.7      547.9 ± 46.1      2.81      0.06[^a^](#T3F1){ref-type="table-fn"}
  210183_x\_at   PNN       pinin, desmosome-associated protein                          4,076.8 ± 556.7   3,036.2 ± 149.6   4,261.8 ± 184.9   3,148 ± 358.9     2.65      0.07[^a^](#T3F1){ref-type="table-fn"}
  214144_at      POLR2D    polymerase (RNA) II (DNA directed) polypeptide D             161.8 ± 14.8      131.9 ± 7.06      136.3 ± 13.4      182.6 ± 19.5      2.5       0.08[^a^](#T3F1){ref-type="table-fn"}
  221649_s\_at   PPAN      peter pan homolog                                            173.8 ± 10.5      152.8 ± 13.8      169.7 ± 18        249.6 ± 50.5      2.51      0.08[^a^](#T3F1){ref-type="table-fn"}
  220553_s\_at   PRPF39    PRP39 pre-mRNA processing factor 39 homolog                  530 ± 46.5        481.7 ± 40.3      535.7 ± 45.5      381.3 ± 47.9      2.35      0.09[^a^](#T3F1){ref-type="table-fn"}
  202126_at      PRPF4B    PRP4 pre-mRNA processing factor 4 homolog B                  1,002.1 ± 52.7    1,075.9 ± 40.8    1,159.1 ± 62.6    1,198.6 ± 71.7    2.37      0.09[^a^](#T3F1){ref-type="table-fn"}
  217857_s\_at   RBM8A     RNA-binding motif protein 8A                                 22.1 ± 4.44       42.5 ± 10.8       34.6 ± 11.8       11.5 ± 1.01       2.56      0.08[^a^](#T3F1){ref-type="table-fn"}
  208307_at      RBMY1J    RNA-binding motif protein, Y-linked, family 1, member J      26.5 ± 5.12       33 ± 14.2         39.3 ± 9.54       78.7 ± 26.8       2.41      0.09[^a^](#T3F1){ref-type="table-fn"}
  209381_x\_at   SF3A2     splicing factor 3a, subunit 2, 66 kDa                        172.1 ± 41.3      223.2 ± 58.3      368.3 ± 62.7      515.8 ± 179.2     2.69      0.07[^a^](#T3F1){ref-type="table-fn"}
  221263_s\_at   SF3B5     splicing factor 3b, subunit 5, 10 kDa                        1,134.9 ± 70.8    955.7 ± 73.6      914.9 ± 29        1,011.1 ± 72.1    2.46      0.08[^a^](#T3F1){ref-type="table-fn"}
  213505_s\_at   SFRS14    putative splicing factor, arginine/serine-rich 14            832.2 ± 47.1      779.5 ± 51        749.8 ± 67.8      630.4 ± 38.6      2.55      0.08[^a^](#T3F1){ref-type="table-fn"}
  204978_at      SFRS16    splicing factor, arginine/serine-rich 16                     949.1 ± 114.7     1,131.2 ± 161.5   1,134.6 ± 118.2   1,803.3 ± 405.1   2.92      0.05[^a^](#T3F1){ref-type="table-fn"}
  212438_at      SNRNP27   small nuclear ribonucleoprotein, 27 kDa (U4/U6.U5)           690.8 ± 102.8     451.6 ± 21.4      410.5 ± 31.7      586.9 ± 111.1     2.72      0.06[^a^](#T3F1){ref-type="table-fn"}
  215722_s\_at   SNRPA1    small nuclear ribonucleoprotein polypeptide A′               232 ± 11.7        296.7 ± 33.1      236.5 ± 19.6      205.4 ± 31.1      2.4       0.09[^a^](#T3F1){ref-type="table-fn"}
  208821_at      SNRPB     small nuclear ribonucleoprotein polypeptides B and B1        337.4 ± 28.8      326.6 ± 15.5      284 ± 26.3        415.6 ± 59.5      2.33      0.1[^a^](#T3F1){ref-type="table-fn"}
  208610_s\_at   SRRM2     serine/arginine repetitive matrix 2                          922.4 ± 118.4     1,019.6 ± 110.7   1,177.7 ± 148.3   1,986.8 ± 611     2.53      0.08[^a^](#T3F1){ref-type="table-fn"}
  206989_s\_at   SRSF2IP   SR-related CTD-associated factor 11                          449.9 ± 27.2      563.6 ± 42.9      572 ± 41.3        486.7 ± 35.9      2.77      0.06[^a^](#T3F1){ref-type="table-fn"}
  201129_at      SRSF7     serine/arginine-rich splicing factor 7 (9G8)                 1,286.8 ± 76.1    1,001 ± 79.4      1,048 ± 100.7     1,008.9 ± 109.5   2.37      0.09[^a^](#T3F1){ref-type="table-fn"}
  202553_s\_at   SYF2      SYF2 homolog, RNA splicing factor                            998 ± 90          1,163.6 ± 71.5    1,307.8 ± 75.3    1,189.4 ± 67.7    2.87      0.06[^a^](#T3F1){ref-type="table-fn"}
  200020_at      TARDBP    TAR DNA-binding protein (TDP-43)                             1,269.4 ± 60.2    1,455.1 ± 135.5   1,201.1 ± 53.4    1,592.9 ± 176.9   2.58      0.08[^a^](#T3F1){ref-type="table-fn"}
  214814_at      YTHDC1    YTH domain containing 1                                      72.1 ± 13.8       118.9 ± 14.2      94 ± 14.4         131.5 ± 22.6      2.7       0.07[^a^](#T3F1){ref-type="table-fn"}
  202126_at      PRPF4B    PRP4 pre-mRNA processing factor 4 homolog B                  2,050.7 ± 211.2   1,330.4 ± 124.9   2,149.5 ± 267.1   2,313 ± 353.5     2.8       0.06[^b^](#T3F2){ref-type="table-fn"}
  200020_at      TARDBP    TAR DNA-binding protein (TDP-43)                             4,252.9 ± 372.4   4,204.2 ± 262.5   3,107.2 ± 229.7   4,109.3 ± 488     2.56      0.08[^b^](#T3F2){ref-type="table-fn"}

GDS810 microarray.

GSE28146 microarray.

###### 

Microarray gene expression changes in the CA1 hippocampus (grey matter laser capture microdissection; GSE28146 microarray)

  Probe          Gene     Control          Incipient         Moderate          Severe            ANOVA F   ANOVA p
  -------------- -------- ---------------- ----------------- ----------------- ----------------- --------- ----------------------------------------
  212262_at      QKI      534.1 ± 33.4     673.4 ± 56.8      758.8 ± 46.4      820.6 ± 100.2     3.45      0.03[^a^](#T4F1){ref-type="table-fn"}
  211271_x\_at   PTBP1    491.9 ± 36.7     568.4 ± 84.5      772.8 ± 72.8      654.6 ± 57.2      3.48      0.03[^b^](#T4F2){ref-type="table-fn"}
  221768_at      SFPQ     794.7 ± 40.6     861.6 ± 83.5      1,137.9 ± 126.6   780.4 ± 104.9     3.95      0.02[^b^](#T4F2){ref-type="table-fn"}
  201129_at      SRSF7    1,286.8 ± 76.1   1,001 ± 79.4      1,048 ± 100.7     1,008.9 ± 109.5   3.79      0.02[^b^](#T4F2){ref-type="table-fn"}
  204978_at      SFRS16   949.1 ± 14.7     1,131.2 ± 161.5   1,134.6 ± 118.2   1,803.3 ± 405.1   3.5       0.03[^b^](#T4F2){ref-type="table-fn"}
  214814_at      YTHDC1   72.1 ± 13.8      118.9 ± 14.2      94 ± 14.4         131.5 ± 22.6      5.59      0.004[^c^](#T4F3){ref-type="table-fn"}

Incipient p \< 0.05 (Fisher LSD);

moderate p \< 0.05 (Fisher LSD);

severe p \< 0.05 (Fisher LSD).

###### 

Correlations: splice-regulatory protein gene expression

                                      r        p
  ----------------------------------- -------- ---------------------------------------
  PTBP1 (GSE28146\] PTBP1 (GDS810)    0.36     0.05
  QKI (GSE28146) QKI (GDS810)         0.48     0.01[^a^](#T5F1){ref-type="table-fn"}
  SFPQ (GSE28146) SFPQ (GDS810)       0.18     0.35
  SRSF7 (GSE28146) SRSF7 (GDS810)     0.50     0.01[^a^](#T5F1){ref-type="table-fn"}
  SFRS16 (GSE28146) SFRS16 (GDS810)   --0.15   0.42
  YTHDC1 (GSE28146) YTHDC1 (GDS810)   0.11     0.57

p \< 0.05.

###### 

Correlations: splice-regulatory proteins and AD susceptibility gene transcripts (GDS810)

                   r        p
  ---------------- -------- -----------------------------------------
  PSEN1, QKI       0.47     0.01
  MAPT, SFRS16     --0.44   0.01
  PSEN2, QKI       0.53     0.002
  PSEN2, SRSF7     --0.42   0.02
  PSEN2, SRSF7     --0.45   0.01
  BDNF, SFPQ       --0.41   0.03
  NTRK2, SFRS16    0.61     0.0003[^a^](#T6F1){ref-type="table-fn"}
  NTRK2, YTHDC1    0.55     0.002
  PSEN1, SFRS16    --0.39   0.03
  APP, QKI         0.49     0.01
  APP, SRSF7       --0.46   0.01
  APP, SFRS16      0.87     0.0000000003
  APP, YTHDC1      0.64     0.0001[^a^](#T6F1){ref-type="table-fn"}
  GRN, PTBP1       0.39     0.03
  NTRK2, SFRS16    --0.65   0.0001[^a^](#T6F1){ref-type="table-fn"}
  APP, SFRS16      --0.54   0.002
  APP, YTHDC1      --0.38   0.04[^a^](#T6F1){ref-type="table-fn"}
  GRN, QKI         0.40     0.03
  PSENEN, SFRS16   --0.55   0.002
  NTRK2, SRSF7     --0.43   0.02[^a^](#T6F1){ref-type="table-fn"}
  NTRK2, SFPQ      0.36     0.05[^a^](#T6F1){ref-type="table-fn"}
  NTRK2, SFRS16    --0.44   0.01[^a^](#T6F1){ref-type="table-fn"}

p \< 0.05 in GDS810 and GSE28146 microarrays.

###### 

Correlations: splice-regulatory proteins and AD susceptibility gene transcripts (GSE28146)

                  r        p
  --------------- -------- ----------
  GRN, SFPQ       --0.45   0.01
  APOE, PTBP1     0.37     0.05
  PSEN1, SFPQ     0.48     0.01
  MAPT, SFPQ      --0.63   0.0002
  NTRK2, QKI      --0.47   0.01
  PSEN1, SFPQ     0.37     0.05
  APP, YTHDC1     0.49     0.01^a^
  GRN, YTHDC1     0.44     0.01
  NTRK2, SRSF7    --0.44   0.02^a^
  NTRK2, QKI      0.44     0.01
  NTRK2, SFRS16   --0.41   0.03^a^
  NTRK2, SFPQ     0.39     0.03^a^
  NTRK2, SRSF7    --0.52   0.003^a^

p \< 0.05 in GDS810 and GSE28146 microarrays.
